U.S. Markets closed
  • S&P Futures

    3,594.25
    +18.25 (+0.51%)
     
  • Dow Futures

    29,723.00
    +177.00 (+0.60%)
     
  • Nasdaq Futures

    11,948.75
    +43.50 (+0.37%)
     
  • Russell 2000 Futures

    1,829.90
    +12.80 (+0.70%)
     
  • Crude Oil

    43.11
    +0.05 (+0.12%)
     
  • Gold

    1,824.60
    -13.20 (-0.72%)
     
  • Silver

    23.38
    -0.26 (-1.09%)
     
  • EUR/USD

    1.1847
    +0.0001 (+0.0118%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3329
    +0.0007 (+0.0493%)
     
  • USD/JPY

    104.5580
    +0.0700 (+0.0670%)
     
  • BTC-USD

    18,382.73
    +123.00 (+0.67%)
     
  • CMC Crypto 200

    367.89
    +6.46 (+1.79%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,173.31
    +645.94 (+2.53%)
     

Syros to Present at Piper Jaffray 31st Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference. Details are as follows:

Piper Jaffray 31st Annual Healthcare Conference:
Date: Tuesday, December 3
Time: 12:30 p.m. ET
Location: The Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the fireside chat will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the fireside chat.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline of development candidates, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in investigational new drug application-enabling studies in cancer. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases, including sickle cell disease. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005056/en/